Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Respitapp - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Respitapp

Approved

STANDARD

Respitapp

Accord Bio Laboratories🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: 7eb928aaf3c23192
Company: Accord Bio Laboratories
Type: Standard

Approval Details

Approval Id: 7eb928aaf3c23192
Drug Approval Philippines Name: Respitapp
Product Name: Respitapp
Registration Number: DR-XY41311
Brand Name: Respitapp
Generic Name: Brompheniramine Maleate + Phenylephrine Hydrochloride
Dosage Form: Syrup
Dosage Strength: 4 mg/ 12.5 mg per mL
Manufacturer: Accord Bio Laboratories
Trader: Le Jumont Pharmaceuticals, Inc.
Issuance Date: 28 June 2021
Expiry Date: 10 October 2026
Classification: Over-the-Counter (OTC) Drug

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

7eb928aaf3c23192

Type

Standard

Back to Philippines FDA Approvals